Advocacy intelligence hub — real-time data for patient organizations
Novartis Pharmaceuticals — PHASE2
Ruijin Hospital
Ruijin Hospital — NA
Swedish Orphan Biovitrum — PHASE3
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Institut National de la Santé Et de la Recherche Médicale, France
Brugmann University Hospital
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
ILARIS
(canakinumab)Orphan drugstandardNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutr...
Mikhail Samsonov
R-Pharm
Masaaki Mori, MD
St. Marianna University Hospital
📍 Fukushima, Fukushima
Sophie Georgin-Lavialle, PHD
INSERM U933
Dan C Nordstrom, MD, PhD, LCSW
Helsinki University Hospital, Department of Medicine
📍 MADISON, WI
Qianjin Lu
Chinese Academy of Medical Sciences
Cem Gabay, Prof.
Hospital University of Geneva